Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
64.91% 67.75% 65.31% 49.47%

+8 more TTM periods

Piotroski F-Score
6 8 7 6
ROA
17.84% 18.27% 17.98% 17.82%
ROIC
19.60% 20.22% 20.99% 19.89%
Return on Tangible Assets
32.75% 32.83% 32.23% 31.40%
Average Days of Receivables
60.20 57.67 54.32 59.91
Free Cash Flow per Share
5.57 5.32 5.15 5.06
Free Cash Flow
2,327.00 2,247.00 2,283.00 2,240.00
Other line items

Show all line items

Columns are period end dates